Introduction
T cell maturation begins when pro-T cells enter the thymus and attempt to generate a functional T cell receptor (TCR). Cells that fail to do so are eliminated through β-selection, but those that succeed must still pass positive and negative (+/-) selection for HLA binding and absence of reactivity to self-antigen in order to survive (Extended Data Fig. 1a,b) . Successful naïve T cells enter the circulation as early thymic emigrants (ETE), and if stimulated by antigen presenting cells in the lymphatic system, they expand and migrate to sites of inflammation to combat harmful agents, a process that resolves through clonal contraction and more T cell death 1 (Extended Data Fig. 1c-e ).
Checkpoint inhibitor (CPI) drugs awaken the immune system so that they attack tumors. CPI have revolutionized cancer care and, over the last decade, have contributed to a 4-fold improvement in the survival of metastatic melanoma patients 2 . Despite these remarkable advances, our understanding of T cell evolution under the selective pressure of CPI is still incomplete and that limits our ability to derive full clinical benefit from these drugs. Consequently, most patients with advanced stage melanoma still die of their disease. Sharing features with responses to infectious diseases [3] [4] [5] , tumor control by the immune system requires coordination between systemic and intra-tumoral immunity 6 , and although several studies have investigated intra-tumoral responses to immunotherapy [7] [8] [9] , few have focused on how CPIs affect the peripheral immune system, or whether changes in peripheral T cells are associated with patient responses 7, 8, 10 .
We hypothesized that because immune responses to tumors mirror normal defensive responses to pathogens, it would be possible to study patient responses to CPI by monitoring peripheral T cell evolution during treatment. T cell receptors (TCR) are generated by errorprone recombination of the TCR locus 11, 12 , creating the enormous diversity needed for effective immune function. This process is ~80% efficient, so most peripheral T cells carry only productive TCR sequences. However, in ~20% of peripheral T cells the first attempts at TCR locus rearrangement failed due to acquisition of stop codons or because the protein coding region was out of frame, so these T cells carry both productive and non-productive TCR sequences 13 . The complementarity determining region-3 (CDR3) of the TCR in particular is highly variable and the sequences are unique to individual T cell clones, so both the productive and non-productive TCR sequences serve as a "fingerprints" for individual T cell clones.
We posited that by sequencing peripheral T cell CDR3 regions, we could track T cell responses to CPI and, because dying cells release their DNA into the circulation, we could also sequence CDR3 regions in cell free DNA (cfDNA) in the blood to monitor T cell turnover in patients receiving CPI. We found an increase in productive TCR sequences in plasma cfDNA of patients who responded to CPI, and this correlated with response. These events were accompanied by evolution of the peripheral T cell repertoire in a manner that mimicked changes induced by anti-viral vaccines. The dynamics of T cell turnover revealed by the cfDNA analysis also correlated with expansion of a specific subset of cytotoxic memory effector peripheral T cells we call immune-effector or T IE cells. Importantly, T IE cell expansion after one cycle of CPI anticipated which patients would go on to respond to treatment. Our data reveal an awakening of the immune system that occurs within 3 weeks of initiating CPI and which anticipates clinical response to first-line therapy. These changes are dynamic and quantifiable and can be monitored with minimally invasive liquid biopsies, features that could be used to identify which patients will benefit from CPI early during their treatment, allowing delivery of more precise treatment planning.
Results

Immunotherapy does not alter thymic output
First, we examined the effects of CPI on thymic function. We used fluorescent-activated cell sorting (FACS, Extended Data Fig. 2 ) to quantify the ETE (CD3 + /CD45RA + /CD45RO -/ CCR7 + /CD27 + /CD31 + T cells 14 ) in peripheral blood mononuclear cells (PBMC) from 50 metastatic melanoma patients (#1-50) receiving first-line anti-PD1 or anti-PD1/anti-CTLA4 treatment (Extended Data Fig. 2i ). As expected 15 , we observed an age-related decrease in ETE levels in pre-treatment (T0) patient blood (Fig. 1a) , but we also found that one cycle of CPI did not affect ETE levels, measured at week 3 (W3)(P=0.274; Fig. 1b) . Next, we examined the TCR excision circle (TREC) in the peripheral T cells of 16 of our patients (#1, [10] [11] [12] [13] 22, [24] [25] [26] [27] 30, 42, [51] [52] [53] [54] . The TREC, a by-product of TCR locus rearrangements, is a non-replicating episome that is diluted when T cells divide 16 (Extended Data Fig. 1a-d) . We found that the TREC:genome ratio in T cells was not affected by CPI (P=0.129, Fig. 1c ).
CPI induce TCR repertoire divergence in peripheral T cells
The observations above indicate that CPI did not affect thymic output in melanoma patients, so to monitor how CPI affected post-thymic T cell evolution, we analyzed the TCR in peripheral PBMC and melanoma metastases. For patient #12 we obtained a fresh tumor biopsy at T0, and whole blood at T0 and after the first cycle of CPI at W3. Using ImReP 17 we identified 16 unique CDR3 DNA sequences from the biopsy and found that 6 of these were also present in the PBMC and cfDNA (Fig. 1d, Table 1 ). Thus, about one third of the sequences in the tumor were also in the periphery, four in pre-treatment PBMC (sequences CDR3 DNA1.1 , CDR3 DNA1.2 , CDR3 DNA2.1 , CDR3 DNA3 ), three in the W3 PBMC (CDR3 DNA1.1 , CDR3 DNA2.1 , CDR3 DNA2.2 ), and one in the W3 cfDNA (CDR3 DNA4 ) (Table  1) . Intriguingly, CDR3 DNA1.1 and CDR3 DNA1.2 both encoded TCR CDR3 prot1 (Table 1) , and CDR3 DNA2.1 and CDR3 DNA2.2 both encoded CDR3 prot2 (Table 1) , suggesting convergence by these TCR on dominant tumor antigens. We also analyzed CDR3 sequences in 18 paired PBMC and TIL from a published melanoma cohort 18 . As an example, at T0 patient #01 presented 123,981 unique CDR3 sequences in the bulk PBMC, 21,052 in the TIL and 3,741 shared sequences (Fig. 1e) , comparable patterns were seen in the other patients (Supplementary Table 1 ).
These data established that tumor resident T cell clones were also present in the periphery, so we called these cells tumor-emigrant PBMC (tePBMC). We compared the clonal relatedness 19, 20 of the CDR3 regions from the tePBMC to the PBMC-private and TILprivate pools. At T0, the tePBMC and TIL-private TCR pools displayed more clonal relatedness than the PBMC-private CDR3 regions (Fig. 1f) , suggesting more TCR convergence in tumor-associated T cells than the bulk PBMC population. At week 3, we did not observe differences in clonal relatedness in the PBMC-private or TIL-private TCR when we compared patients who achieved disease control (DC) at week 12 with those who developed progressive disease (PD) (Extended Data Fig. 3a) . Similarly, when we compared clonal relatedness in the PBMC-private TCR at T0 and W3, we did not observe differences between DC or PD patients, whereas in the tePBMC pool, there was a significant reduction in TCR clonal relatedness in patients who achieved PD, but not in patients who had PD (Fig.  1g) . This suggests recruitment of T cells with a broader TCR repertoire from the periphery to the tumors of patients who responded, but not to the tumors of patients who did not respond.
CPI induce peripheral T cell turnover
Next, we compared the CDR3 clonal relatedness in PBMC and cfDNA of 28 CPI-treated metastatic melanoma patients (#11-27,#29-39). In T0 blood from patient #27 we observed 14,112 unique CDR3 sequences in the bulk PBMC, 844 in the cfDNA and 193 shared sequences (Fig. 2a) . Comparable patterns were seen in the other 27 patients (Supplementary  Table 2 ). Intriguingly, the number of unique PBMC/cfDNA-shared CDR3 sequences increased after one cycle of CPI (Fig. 2b) , so we investigated how CPI affected the immunerecognition landscape in these pools. At T0 the PBMC-private CDR3 clonal relatedness was ~0, but was significantly higher in both the cfDNA-private and PBMC/cfDNA-shared pools (Fig. 2c) . Critically, clonal relatedness in the PBMC/cfDNA-shared pool decreased significantly in patients who achieved DC at week 12, but not in patients with PD (Fig. 2d) , suggesting repertoire divergence in the T cells that turnover in the responding patients.
The cfDNA CDR3 sequences come from T cell turnover in the thymus and periphery and contain both productive and non-productive sequences (Extended Data Fig. 1 ). We used ImmunoSeq to quantify productive (reading frame intact) and non-productive (out of frame, stop codon) CDR3 sequences and calculate a Rearrangement Efficiency Score (RES; productive/[productive+non-productive]). In healthy donors (HD) the PBMC RES was ~0.8 as expected 13 , but in cfDNA the RES was 0.44 (P<0.001; Fig. 2e ), presumably from nonproductive TCR sequences released by T cells failing β-selection in the thymus. The T0 PBMC and cfDNA RES (RES T0 ) values were similar in HD and patients (Fig. 2e) , suggesting that melanoma does not overtly affect the efficiency of T cell rearrangements in the thymus and also that it does not affect bulk T cell turnover in the periphery. We therefore compared the RES in PBMC and cfDNA at T0 and W3 to generate difference scores (Δ W3 RES) and measure how CPI affects T cell rearrangement and turnover during the first cycle of immunotherapy. The PBMC Δ W3 RES measured changes in TCR rearrangement efficiency and was ~0 irrespective of whether the patients responded or not (Fig. 2f) . Thus, CPI did not affect TCR rearrangement efficiency in the thymus, meaning that the cfDNA Δ W3 RES measured the changes in the peripheral T cell turnover alone. Notably, the cfDNA Δ W3 RES rose from ~0 in patients with PD to 0.09 (P=0.037) in patients who achieved DC at 12 weeks (Fig. 2f) . Thus, CPI increased peripheral T cell turnover in responding patients, but not in non-responding patients.
CPI stimulate expansion of specific peripheral T cell subsets
Our data reveals dynamic TCR repertoire reorganization during T cell expansion/contraction in responding patients, so we used high dimensional FACS to characterize peripheral T cell subsets and monitor T cell evolution under CPI (Extended Data Fig. 2) . We found that a CD8 + memory effector cytotoxic T cell subset that we called immune-effector T cells (T IE ) expanded proportionally to the cfDNA Δ W3 RES (Fig. 3a) . T IE cells are characterized by the surface phenotype CD3 + /CD4 -/CD8 + /CD45RA -/CD45RO high /CD27 -/CCR7 -(Extended Data Fig. 1k ) and have been shown to be associated with response to infections 21, 22 .
To study cytotoxic T cell turnover, we sequenced the TCR in T0 and W3 purified CD8 + peripheral memory and naive T cells from 3 PD and 3 DC patients (#12, [16] [17] [18] [19] 29) . More than other peripheral T cell subsets, the T IE cells had the highest similarity to cfDNA CDR3 sequences ( Fig. 3b) and presented the highest clonality (Fig. 3c ). This suggests T IE cells are actively turning over, but with convergence towards dominant clones. Moreover, although it is not yet possible to establish if the T IE cell CDR3 regions recognized neo-epitopes, largely these cells did not express TCR known to recognize public epitopes such as Melan-A or viral proteins (Supplementary Table 3 ). In patient #12, from whom we obtained a biopsy, we identified identical CDR3 sequences in the tumor and the peripheral T IE cells (Fig. 3d) , demonstrating that individual T IE clones coexisted in the tumor and periphery. Moreover, expansion of intratumoral cells with the T IE phenotype is reported to be associated with responses to CPI 23 , and we used published CyTOF data 24 to confirm that T IE cells were resident in melanoma and renal cell carcinoma (immune-responsive tumors), but were negligible in glioblastoma (immune-refractory tumor) and tonsils ( Fig. 4a-d) .
Next, we analyzed PBMC from 30 CPI-treated metastatic melanoma patients from our cohort (#1-30) and show that the T IE cells expanded at W3 in patients who achieved DC, including late responders, but not patients with PD (P=0.0007; Fig. 5a ), irrespective of therapy protocol (P=0.200, Fig. 5b) . Notably, despite a W3 T IE expansion of ~20%, the W12 CT scan revealed that patient #20 was progressing (Fig. 5a) . Unfortunately, the patient died of complications so a late response could not be measured, but from day 40 we observed a steady decline in this patient's NRAS Q61R circulating tumor DNA (ctDNA) 25 (Fig. 5c) , revealing that consistent with the observed expansion in T IE cells, the patient achieved a biochemical response (Fig. 5c ). An increase of >0.8% in the T IE ratio relative to all CD8 + memory T cells at W3 was associated with increased overall survival and segregated DC (including late-responders) from PD patients with sensitivity = 0.94 and specificity = 0.79 (accuracy = 0.87 and area under the curve [AUC] = 0.85) (Fig. 5d ). The Hazard Ratio for patients without W3 T IE expansion was 3.7 (95% CI 1.12-11.9, P=0.032) (Fig. 5e) . We confirmed these observations in an independent cohort of 20 CPI-treated patients (#31-50, Fig. 5f ,g), with sensitivity = 0.82 and specificity = 1 (accuracy = 0.90, AUC = 0.92). By week 9, T IE cells no longer discriminated DC from PD patients (Extended Data Fig. 4a ). Accordingly, when we analyzed published CyTOF data 3 , we confirmed T IE to be a distinct T cell subset in PBMC of patients with metastatic melanoma (Extended Data Fig. 4b,c ), but consistent with our findings, the T IE levels at week 12 did not distinguish DC from PD patients (Extended Data Fig. 4d ). Thus, changes at W3 were prognostic for melanoma responses to CPI, but were no longer prognostic by W9 or W12, demonstrating the dynamic nature of these responses and consistent with a previous study showing that the peak of immune activation is at W3 7, 10 .
We note that the W3 T IE expansion identified patients who achieved DC early during treatment with superior accuracy to the W3 peripheral T lymphocyte invigoration to tumor burden ratio (Ki67/TB), where the accuracy = 0.64 (16/24 patients with Ki67/TB>1.94 had an objective response compared to 3/17 patients with Ki67/TB<1.94) 7 . We note also that the W3 T IE expansion also had greater accuracy than PD-L1 staining in pre-treatment melanoma biopsies where the accuracy in a phase III clinical trial = 0.67 (78/148 patients with PD-L1 positive biopsy had an objective response compared to 89/270 patients with PD-L1 negative biopsy) 26 .
Next, we analyzed published single cell RNA expression and protein sequencing (REAPSeq) data from healthy donors 27 and found that T IE cells have the additional surface phenotype CD69 + /PD1 low/dim /TIGIT + /CD25 +/-/CD155 + /CD40 med/high /CD154 med/high / CD357 med/high and a distinct transcriptome signature including immune-activation genes (cluster 9 in Extended Data Fig. 5a ,b and Supplementary Table 4 ). Our analysis of this data also showed that T IE cells expanded from healthy donor CD8 + naive PBMC following in vitro stimulation, and that they expressed genes associated with immune-effector function (Extended Data Fig. 5c-d ). Using FACS analysis of 5 patients' PBMC (#1,24,29,42,54) we observed a trend for T IE reinvigoration (increased Ki67 + expression) after 1 cycle of CPI (Extended Data Fig. 6a ), although the limited sample size could not support robust conclusions. Note that the W3 T IE expansion was not associated with toxicity, but expansion of a separate T regulatory (T reg ) subset characterized by surface phenotype CD3 + / CD4 + /CD8 -/CD25 + /CD127 -/low28 correlated with toxicity grade (Fig. 6a,b ).
CPI induce peripheral T cell repertoire rearrangements
Our findings revealed intriguing parallels between immune responses to infection 21, 22 and CPI, and we hypothesized that immune responses to CPI mirror the defense against pathogens. To test this, we compared T cell repertoire rearrangements in people receiving vaccination or CPI. Using published data 29, 30 , we calculated T cell clonality (measures clone dominance) and diversity (indicates heterogeneity) and note that 1-2 weeks after antiviral vaccines were administered, healthy donor TCR repertoires presented bifurcated reorganization with either increased clonality or increased diversity (Fig. 7a) . We next compared clonality (Δ W3 clonality) and diversity (Δ W3 diversity) in T0 and W3 PBMC from 17 CPI-treated metastatic melanoma patients (#11-27). In patients who went on to achieve DC at week 12 we observed bifurcated reorganization of the TCR repertoire, with substantially increased clonality or diversity, whereas no such response occurred in patients with PD ( Fig. 7b ). Using our training cohort, we developed a linear discriminant analysis (LDA) algorithm that at W3 classified patients according to response (assessed at week 12) with an accuracy of 0.9 (specificity=1 and sensitivity=0.8). We validated these findings in an independent cohort of 27 patients with advanced melanoma 7, 31 , and again found a bifurcated TCR repertoire reorganization in DC, but not PD patients (Fig. 7c ). Our LDA accuracy for response prediction was 0.77 in this validation cohort.
Discussion
We examined how the selective pressure of a single cycle of CPI affects peripheral T cell evolution in previously untreated metastatic melanoma patients. We found that CPI induced immune-awakening that was revealed by increased levels of productive CDR3 sequences released into the blood and dynamic changes in the TCR repertoire. CPI did not affect thymic output but did induce peripheral T cell turnover and this correlated with the expansion of a CD8 + cytotoxic memory effector subset that was CCR7 -/CD27 -. This subset of lymphocytes is involved in cytotoxic response to infections 32, 33 and we have now established that they are also associated with CPI responses. Immune effector cells are the cells of the immune system that support anti-cancer immune surveillance 34 , and since our data has identified a specific T cell subset involved in this network, we called them immuneeffector T cells, or T IE cells.
It was recently shown that following CPI treatment, the expansion of tumor infiltrating T cell clones did not come from pre-existing TIL 35 , but rather from novel clonotypes, most probably in the peripheral compartment. Those observations are consistent with a model that the tumor is an open compartment with active cross-talk with the peripheral immune-system and accordingly, in responding patients we observed a significant early T cell repertoire rearrangement in the fraction of TIL circulating in the blood, and which we call tumor emigrant T cells or tePBMC.
Clonotype modulation by checkpoint blockade has been described previously, largely in the tumor microenvironment 7,36-38 , but we determined that the pattern of peripheral turnover and overall repertoire rearrangement of T cells in blood identify the patients with an effective immune-awakening and who will go on to respond to CPI. It has also been shown in animal models that anti-CTLA4 and anti-PD1 drugs induce distinct cellular reactions 39 . That we did not observe significant differences between single-agent and anti-PD1/CTLA4 combined therapy supports that our observations reflect the final effects needed for tumor elimination, and importantly we showed that these changes could be detected in the periphery. Although we could not discriminate if the T cell clones driving these changes were melanoma-specific, or if this reflected a general, off-target immune-activation, our results nonetheless contribute to our understanding of the dynamics of immune-system evolution after one cycle of CPI. That these responses also occur with infection could limit specificity in the CPI setting, necessitating further kinetic analysis and clinical validation, but our results have established that these responses could provide tractable tools for the delivery of precision immunotherapy. Moreover, our hypothesis-generating results contribute to improved understanding of immune system biology and they could have broader implications beyond the oncoimmunology field.
Note that CCR7 and CD27 were downregulated in T IE cells, and that phenotype has been associated with differentiated effector T cell release from lymph nodes to the periphery [40] [41] [42] [43] . Also in line with previous observations that in vitro stimulation of CD8+ T cells induced downregulation of CD27 and CCR7 44, 45 , our analysis of previous data showed that T IE cells expanded following in vitro stimulation. Our data also showed that the expansion of these cells after one cycle of CPI identified the patients for whom therapy overcame melanomainduced immune-suppression. Within the scope of this study, we have not analyzed the antitumor reactivity of T IE cells, but our data showed that peripheral T IE clones infiltrated melanoma and represent an abundant fraction of tumor infiltrating lymphocytes with high repertoire clonality. The T IE were also in active turn-over. The relatively small size of our sample could limit the generalization of our results, but both T IE and TCR peripheral repertoire reorganization could identify which patients will benefit from CPI with greater accuracy than standard biopsy PD-L1 staining or Ki67/TB. Future research will investigate the anti-tumor cytotoxicity and specificity of these cells, and their potential for clinical development.
In summary, here we identified a peripheral blood early immune-signature characterized by significant rearrangements of the peripheral T cell repertoire and by turnover of specific T cell subsets. Critically, the magnitude of the immune-signature changes after the first cycle of therapy anticipated which patients would go on to respond and were detected in the blood, providing the advantages inherent in minimally invasive liquid biopsies. Although further studies are required to determine the mechanisms underpinning our observations and their specificity for CPI-induced responses, our research provides a strategy to analyze immune cell evolution under the selective pressure of CPI. Our findings advance our knowledge of immune system responses to immunotherapy, and critically they provide a potentially tractable tool to identify which patients will benefit from CPI early during treatment. This could help clinicians to stratify their patients more effectively to thereby improve personalization of therapeutic planning. 
cfDNA analyses
Extraction and quantification of cfDNA was carried out as described previously 46 for patients #11 to #27 and #29 to #39. In patients #1, #10, #11, #12, #13, #22, #24, #25, #26, #27, #30, #42, #51-54 an aliquot of PBMC was frozen in FBS+10 % DMSO immediately after separation and then thawed and stained with CD3 fluorescent antibody as per above; CD3 + cells were sorted with Aria III (BD Biosciences) and used for the TREC quantification.
FACS analysis
T IE cells were quantified as the percentage of CD27 -/CCR7 -cells in the CD3 + /CD8 + / CD45RO + /CD45 -gate (Extended Data Extended Data Fig. 1 ). Gating strategy is shown in Extended Data Extended Data Fig. 1 .
TREC
TREC analysis was performed using frozen PBMC for patients #1, #10, #11, #12, #13, #22, #24, #25, #26, #27, #30, #42, #51-54. TREC quantification was performed with droplet digital polymerase chain reaction (ddPCR) using custom TREC assay (TREC forward primer 5'-CACATCCCTTTCAACCATGCT-3' at final concentration 450nM, TREC reverse primer 5'-GCCAGCTGCAGGGTTTAGG-3' at final concentration 450nM and HEX-Black Hole probe 5'-ACACCTCTGGTTTTTGTAAAGGTGCCCACT-3' at final concentration 250nM, as per C Falci et al. 47 , Sigma-Aldrich, Dorset, UK). For ddPCR, the TREC assay was added to 20ng DNA from sorted CD3 + peripheral T cells, 11μL ddPCR Supermix for Probes (NodUTP) (Bio-rad, Hercules, CA) and 1.1μL of TERT TaqMan Copy Number Reference Assay (Thermo Fisher Scientific, Waltham, MA) in a total volume of 22μL. Droplets were generated and analyzed using the QX200 AutoDG ddPCR system according to the manufacturer's instructions (Bio-Rad, Hercules, CA, USA). Cycling conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds; 55°C for 1 minute; Kit (Zymo, Irvine, USA). Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen, Manchester, UK) and Sanger sequencing using the T7 5'-TAATACGACTCACTCTAGGG-3' and SP6 5-ATTTAGGTGACACTATAG-3' primers was used to confirm correct insert identity. The final plasmid was designated TREC-plasmid.
RNA sequencing
RNA was extracted from a pre-treatment human fresh frozen tumor sample for one patient with available tissue (patient #12) using AllPrep DNA/RNA kit (Qiagen, Manchester, UK) according to manufacturer's instructions. Indexed PolyA libraries were prepared using 200ng of total RNA and 14 cycles of amplification with the Agilent SureSelect Strand Specific RNA Library Prep Kit for Illumina Sequencing (Agilent, G9691B, Santa Clara, CA, US). Libraries were quantified by qPCR using the KAPA Library Quantification Kit for Illumina platforms (Kapa Biosystems Inc., KK4873, Wilmington, MA, US). Paired-end 100bp sequencing was carried out by clustering 15pM of pooled libraries on the cBot and sequenced on the Illumina HiSeq 2500 in high output mode using TruSeq SBS V3 chemistry (Illumina Inc., San Diego, CA, US). After removing adapters using Cutadapt (v1.14) and trimming poor quality base calls using Trimmomatic (v0.36) 49 , the human reads were aligned to GRCh37 (release 75) using STAR (v2.5.1) aligner 50 , respectively.
TCR analysis
TCR sequences were inferred from RNA Seq data from one patient for which we had a frozen pre-treatment metastasis biopsy sample using ImReP. 17 ImmunoSEQ® TCRb Assay kit (Adaptive Biotechnologies, Seattle, WA, USA) was used to amplify and sequence TCR sequences in cfDNA and PBMC's DNA as per manufacturer's instructions. We loaded the same DNA input for all PBMC (350ng, patients #11 to #39) and cfDNA (40ng, patients #11 to #27 and #29 to #39) samples, while for the sorted T cell subsets (for patients #12, #16, #17, #18, #19, #29) we loaded all the DNA extracted from the sorted cells. A metafile will be available with each single sample and anonymous patient information. Pooled libraries were quantified by qPCR using the KAPA Library Quantification Kit for Illumina platforms (Kapa Biosystems Inc., KK4873, Wilmington, MA, US). Sequencing was carried out by clustering 0. 18 (TCR sequencing data were downloaded from EGAS00001003178 EGA study accession dataset EGAD00010001608, patient clinical history metadata file from EGAD00001004352). Consecutive patients #11 to #27 from The Christie NHS Foundation Trust constituted the training cohort. The external validation data were pooled from the cohorts of patients from an independent cohort of patients from The Christie NHS Foundation Trust (patients #28 to #39), a cohort of metastatic melanoma patients from AC Huang et al. 7 (PBMC CD38 + plus PBMC CD38 -merged populations from patient #12288, #13471, #14746 and #14835; TCR sequencing data were kindly made available by the Authors) and the cohort of locally-advanced treatment naive melanoma patients from referenced accession Amaria et al. 18 (patients #01, #02, #04, #05, #06, #07, #08, #010, #011, #013, #015; TCR sequencing data were downloaded from EGAS00001003178 EGA study accession dataset EGAD00010001608, patient clinical history metadata file from EGAD00001004352). Gini coefficient was used as a measure of clonality 51 and calculated with the function clonality from LymphoSeq R package. Clonal relatedness was calculated with clonalRelatedness LymphoSeq function, and similarity was assessed by means of Bhattacharyya coefficient using bhattacharyyaMatrix LymphoSeq function. The diversity was calculated using Renyi index (α=1) as per Spreafico et al. 52 , with time point pairwise analysis for each single patient. 
CyTOF surface phenotype analysis
Differential marker expression analysis was performed on CyTOF (cytometry by time-offlight mass spectrometry) data from Krieg et al. 8 and Greenplate et al. 24 downloaded from a publicly available repository (referenced accession https://flowrepository.org/experiments/ 1124 and http://flowrepository.org/id/FR-FCM-ZZMC), using the custom workflow described in Nowicka et al. 53 . All analyses on CyTOF data were performed after arcsinh (with cofactor=5) transformation of marker expression and correction for batch effect (function removeBatchEffect from limma R package). The T IE subset was identified by differential expression of T lymphocytic markers CD3, CD8a, CD45RA CD45RO, CCR7 and CD27. Cell populations clustering was obtained with R package FlowSOM after the metaclustering step (ConsensusClusterPlus R package). 
Statistics and Reproducibility
Unless otherwise stated, all statistical tests were two-tailed. The statistical differences between two groups for numerical variables were assessed using two-tailed 
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Valpione et al. as an episome in the nucleus. The TREC does not replicate so is diluted during subsequent cell divisions. b T cells with a functional TCR undergo positive and negative selection (+/-selection) for HLA and self-antigen recognition. The CDR3 DNA from T cells eliminated during this step is released into the blood. c Naive T cells enter the circulation as early thymic emigrants (ETE). d T cells primed by antigen presenting cells (APC) in the lymphatic system undergo clonal expansion, which dilutes the TREC amongst the daughter cells. e T cell homeostasis is maintained by subsequent contraction (turnover cycles), releasing further CDR3 DNA into the blood. 
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Refer to Web version on PubMed Central for supplementary material. also present in peripheral PBMC and cfDNA for one patient at T0 and W3. See Table 1 Table 1 Tumor infiltrating T lymphocyte (TIL) CDR3 sequences also present in peripheral PBMC and cfDNA for patient #12 at T0 and W3.
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